Short answer
Ginkgo Bioworks Holdings, Inc. (DNA) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 business-performance presentation scheduled for November 5, 2026 at 4:30 p.m. ET.
Ginkgo Bioworks Holdings, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Q3 2026 business-performance presentation scheduled for November 5, 2026 at 4:30 p.m. ET
- Webcast, investor Q&A, and replay available through Ginkgo’s investor-relations website
- No operating or financial results disclosed in this 7.01 notice
- Ginkgo identifies SEC filings, websites, and social media as potential channels for material investor information
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 results presentation scheduled for November 5, 2026, at 4:30 p.m. ET
- Results cover quarter ended September 30, 2026
- Investor webcast and Q&A may provide updated operating performance and outlook
- Presentation details and replay available through Ginkgo’s investor relations website
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Ginkgo Bioworks Holdings, Inc. 8-K filings
Get the next DNA 8-K as it lands
Follow DNA for push alerts, or ask the research agent what this filing means.